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Abstract
Background: Diagnostic codes from electronic health records are widely used to assess patterns of disease. Infective
endocarditis is an uncommon but serious infection, with objective diagnostic criteria. Electronic health records have
been used to explore the impact of changing guidance on antibiotic prophylaxis for dental procedures on incidence,
but limited data on the accuracy of the diagnostic codes exists. Endocarditis was used as a clinically relevant case study
to investigate the relationship between clinical cases and diagnostic codes, to understand discrepancies and
to improve design of future studies.
Methods: Electronic health record data from two UK tertiary care centres were linked with data from a prospectively
collected clinical endocarditis service database (Leeds Teaching Hospital) or retrospective clinical audit and microbiology
laboratory blood culture results (Oxford University Hospitals Trust). The relationship between diagnostic codes
for endocarditis and confirmed clinical cases according to the objective Duke criteria was assessed, and impact on
estimations of disease incidence and trends.
Results: In Leeds 2006–2016, 738/1681(44%) admissions containing any endocarditis code represented a definite/
possible case, whilst 263/1001(24%) definite/possible endocarditis cases had no endocarditis code assigned. In Oxford
2010–2016, 307/552(56%) reviewed endocarditis-coded admissions represented a clinical case. Diagnostic codes used
by most endocarditis studies had good positive predictive value (PPV) but low sensitivity (e.g. I33-primary 82% and 43%
respectively); one (I38-secondary) had PPV under 6%. Estimating endocarditis incidence using raw admission
data overestimated incidence trends twofold. Removing records with non-specific codes, very short stays and
readmissions improved predictive ability. Estimating incidence of streptococcal endocarditis using secondary
codes also overestimated increases in incidence over time. Reasons for discrepancies included changes in
coding behaviour over time, and coding guidance allowing assignment of a code mentioning ‘endocarditis’
where endocarditis was never mentioned in the clinical notes.
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Conclusions: Commonly used diagnostic codes in studies of endocarditis had good predictive ability. Other apparently
plausible codes were poorly predictive. Use of diagnostic codes without examining sensitivity and predictive ability can
give inaccurate estimations of incidence and trends. Similar considerations may apply to other diseases. Health record
studies require validation of diagnostic codes and careful data curation to minimise risk of serious errors.
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Background
Electronic health records are a powerful resource, enab-
ling large observational analyses to be undertaken to
assess disease outcomes, monitor trends and assess the
effectiveness of healthcare. Their routine collection means
that their use in research does not place an additional data
collection burden on National Health Service (NHS) staff.
Identification of diseases in health records is frequently
based on analysis of the World Health Organization ICD-
10 [1] diagnostic codes assigned to a patient’s hospital ad-
mission. Whilst the process of recording these codes upon
discharge is internationally standardised and audited,
these codes are recorded principally for reimbursement
and administration, and multiple sources of potential
error exist in the process of assigning codes [2, 3]. Previ-
ous studies have shown how coded data can create arte-
factual patterns in mortality [4].
Endocarditis is a useful and clinically relevant ‘test case’
for studying electronic health record accuracy. It benefits
from having objective clinical criteria for defining true
diagnoses and shares little overlap with other conditions.
Additionally, the low overall incidence of infective endo-
carditis, even in high-risk populations, means that very
large-scale and resource-intensive individually randomised
controlled trials would be required to test the benefits of
preventative interventions. Thus, electronic health record
studies have been particularly important in guiding the
management of infective endocarditis.
Numerous studies have been performed worldwide to
assess the impact of changes to recommendations on the
use of antibiotic prophylaxis to prevent infective endocarditis
[5–10], with a lack of clear consensus [11–23] (summary in
Additional file 1: Table S1 and Table S2). Some studies have
found no significant change in disease trends after guidelines
stopped recommending routine antibiotic prophylaxis for a
broad range of at-risk individuals. Other studies suggest that
any increase in overall incidence may be driven by an in-
creasing population of ‘at-risk’ older adults, including indi-
viduals with predisposing heart conditions and prosthetic
devices [19]. The largest studies suggesting an increase in
endocarditis incidence after guidelines changed used US
health insurance data [24], and English Hospital Episode Sta-
tistics (HES) data [14]. Given the lack of randomised con-
trolled trials, these studies form some of the best
available evidence; it is therefore important that the
validity and accuracy of coding data, which these
studies use, are comprehensively assessed.
The largest study investigating accuracy of endocarditis
coding considered 1673 hospitalisations at a US centre
and found that sensitivity for identifying true infective
endocarditis cases ranged from 21.1 to 97.2% depending
on the definition of endocarditis, and diagnostic codes in-
cluded [19]. In contrast, endocarditis coding quality in
England has not been explored in detail to date; this is
particularly relevant because an English study suggested
increasing incidence after changes in dental prophylaxis
[14]. Given the importance of electronic health record
data in endocarditis, and the utility of endocarditis as a
case study given differences in coding algorithms in previ-
ous studies (Additional file 1: Table S2), we investigated
the quality of endocarditis diagnostic coding data in two
English tertiary care centres, combining retrospective
audit, service evaluation, linked electronic health record
and microbiology data. Admissions with an endocarditis
diagnostic code were compared with recorded cases of in-
fective endocarditis based on objective criteria, incidence
trends in coded and confirmed clinical cases were assessed
and reasons for discrepancies were explored.
Methods
Study population
Coding was studied in Leeds Teaching Hospital NHS Trust
(Leeds), comprising seven tertiary and secondary care cen-
tres, directly serving a population of 780,000 with 1785
beds, and in Oxford University Hospitals NHS Foundation
Trust (Oxford), a teaching hospital with three associated
tertiary care centres, serving a population of 655,000 with
1465 beds [25].
Identifying diagnostic codes for infective endocarditis and
secondary organisms
We reviewed all diagnostic codes from the WHO ICD-
10 Version 5 containing the word ‘endocarditis’, together
with codes used in previous publications related to in-
fective endocarditis and causative organisms in elec-
tronic health records (including ICD-10 equivalents of
ICD-9 codes) [11, 13, 17–20, 22, 26, 27], and codes used
for confirmed clinical endocarditis cases in a 2016 audit
of Oxford data. These were reviewed by three clinicians
(NJF, BY, LP) and the Oxford clinical coding team (CM,
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SW) and classified as ‘included in study’ (represents infect-
ive endocarditis of non-viral aetiology) or ‘not included’
(represents disease entity other than as defined by standar-
dised criteria), or ‘not present in UK data’ (Table 1). Sup-
plementary codes representing specific organisms were
similarly reviewed and classified as representing the most
common causative pathogens, Streptococcus spp.,
Staphylococcus spp. or others (Additional file 1: Table S3).
Data sources
Clinical cases of infective endocarditis: endocarditis service
database (Leeds) and clinical audit (Oxford)
In Leeds, patients with suspected infective endocarditis
referred by physicians across all sites have been reviewed
by a dedicated team prospectively since 1 January 2006
and clinical details recorded in the Leeds Endocarditis
Service Database, including modified Duke criteria [28, 29]
(definite, possible, rejected [i.e. investigated and excluded]),
causative organism genus, local patient identifier and ad-
mission dates (Additional file 1: Figure S1). Electronic notes
for admissions 2006–2016 with an endocarditis code but
no corresponding record in the endocarditis service data-
base were also reviewed retrospectively as part of a service
evaluation exercise.
In Oxford, electronic and paper notes from endocarditis-
coded admissions 2010–2016 were retrospectively reviewed
in an audit of endocarditis coding (Additional file 1:
Extended Methods).
Table 1 ICD-10 Endocarditis codes and corresponding ICD-9 codes (and clinical modifications)
ICD-10 Code Description Corresponding ICD-9
Code/ICD-9-CM code
Description
Included
I33 (I330) Acute and subacute infective endocarditis 4210 Acute and subacute infective endocarditis
I38 Endocarditis, valve unspecified 4249 Endocarditis valve unspecified cause
(I38.X) 42499 Other endocarditis valve unspecified
I339 Acute and subacute endocarditis, unspecified 4219 Acute endocarditis unspecified
T826 Infection and inflammatory reaction due to
cardiac valve prosthesis
99661 Infection and inflammatory reaction due to cardiac
device implant and graft
B376 Candidal endocarditis 11281 Candidal endocarditis
I39 Endocarditis and heart valve disorders in
diseases classified elsewhere
11504 Histoplasma capsulatum endocarditis
(I390) Histoplasma duboisii endocarditis
11514 Histoplasmosis endocarditis
11594 Acute and subacute infective endocarditis in diseases
classified elsewhere
4211 Endocarditis in diseases classified elsewhere
I398 Endocarditis, valve unspecified, in diseases
classified elsewhere
42491
Not included
I423 Endomyocardial (eosinophilic) disease 4250 Endomyocardial fibrosis
I091 Rheumatic diseases of the endocardium,
valve unspecified
3979 Rheumatic diseases of the endocardium valve
unspecified
T827* Infection and inflammatory reaction due to
other cardiac and vascular device, implants
and grafts
99661 Infection and inflammatory reaction due to cardiac
device implant and graft
99662 Infection and inflammatory reaction due to vascular
device implant and graft
I011 Acute rheumatic endocarditis 3911 Acute rheumatic endocarditis
Codes that feature only US specialised coding guidance (ICD-10-CM 2010) [27], not in UK datasets
A3951 Meningococcal endocarditis 3642 Meningococcal endocarditis
A3282 Listerial endocarditis 42491 Endocarditis in diseases classified elsewhere
A5203 Syphilitic endocarditis 42491 Endocarditis in diseases classified elsewhere
B3321 Viral endocarditis 7422 Coxsackie endocarditis
A5483 Gonococcal heart infection 9884 Gonococcal endocarditis
*The T827 code (‘Infection and inflammatory reaction due to other cardiac and vascular device, implants and grafts’) was not selected as a review of the Oxford
2016 audit data suggested it was overwhelmingly used for wound infections after surgery, and the number of admissions with a primary or secondary T827 code
was greater than all other endocarditis-coded admissions combined
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As this did not provide information on endocarditis
cases which did not receive an endocarditis diagnostic
code, we additionally reviewed notes from all patients
who had antibiotics prescribed for infective endocarditis
in Jan-Dec 2016, within a service evaluation of antibiotic
prescribing (Additional file 1: Figure S3). Data prior to
2016 were not available as electronic prescribing was
only implemented in late 2015.
Electronic health record data
In Leeds, electronic health record data were extracted
from hospital databases as part of a service evaluation
exercise for all admissions of patients in the Leeds Endo-
carditis Service Database, and all admissions with an
endocarditis diagnostic code 2006–2016 inclusive. In
Oxford, electronic health record data were extracted
from hospital databases for all admissions during 2010–
2016 with an endocarditis code, and for 2016 for admis-
sions with a prescription indicating endocarditis. Data
were extracted separately from an anonymised linked
data warehouse [30] for all admissions with an endocardi-
tis code from 1999 to 2016 for epidemiological analyses.
Microbiological data on causative organisms
For Leeds, organisms causing endocarditis were recorded
by the clinician at diagnosis, based on microbiology results
from a fully accredited UK microbiology laboratory, which
followed standardised procedures in bacterial culture,
identification and susceptibility testing [31–33]. For the
Oxford 2010–2016 audit, causative organism was based
on the organism recorded in the medical notes. For the
Oxford 1999–2016 epidemiological analysis, causative
organism was the organism isolated from blood culture
(or Bartonella/Coxsiella serological testing) taken closest
to the date of admission and during the admission, or up
to 7 days preceding the admission if no organism was iso-
lated during the admission. Organism identification was
from a similarly accredited UK microbiology laboratory.
Variables
Anonymised electronic health record data extracted in
Oxford and Leeds included admission/discharge dates,
method of admission/discharge and all diagnostic codes
from all consultant episodes. In Oxford, data on blood
cultures and Bartonella/Coxsiella serological testing as
above were included from the anonymised linked data
warehouse [30].
Data processing
Defining endocarditis cases
All cases (Leeds) and admissions (Oxford audit) evaluated
as fulfilling modified Duke criteria [28, 29] for possible or
definite endocarditis were included in the analysis. Briefly,
this guidance identifies major criteria (such as repeated
blood cultures positive for typical microorganisms and
echocardiographic demonstration of valvular involvement)
and minor criteria (such as fever, predisposing factors,
limited microbiological evidence and other systemic fea-
tures). Definite cases fulfilled 2 major criteria, 1 major cri-
terion and 3 minor criteria or 5 minor criteria. Possible
cases fulfilled 1 major criterion and 1 or 2 minor criteria,
or 3 minor criteria.
Classifying admissions in electronic health record data
An admission was defined as a hospital provider spell
(‘the total continuous stay of a patient [..] on premises
controlled by a Health Care Provider’) according to NHS
Business definitions [34]. Each spell comprised a number
of consultant episodes, each with a primary ICD-10 code
(the main condition treated or investigated) and up to
20 secondary codes for other relevant conditions and/or
supplementary codes, e.g. reflecting organisms isolated
(subsequently denoted ‘secondary codes’). An admission
with an endocarditis code was defined as any spell where
an infective endocarditis code was used in any position of
any consultant episode. If more than one endocarditis code
was used during the spell, the primary code(s) was priori-
tised followed by secondary codes, with code priority being
I33.0>I33.9>I39.0>139.8>I01.1>I09.1>I42.3>B37.6>T82.6>
I38.0 based on a priori clinical plausibility and use in previ-
ous studies (Table 1 and Additional file 1: Table S1). For
admissions matched to an infective endocarditis case with
no associated endocarditis code, we chose the dominant
episode using previously reported methods to assess the
coded reason for admission [35].
Data matching
All cases of infective endocarditis identified in the Leeds
Service Database or Oxford 2016 prescribing evaluation
were matched to admissions in electronic health record
data, based on local patient identifier and nearest admis-
sion/discharge dates. In cases of multiple matches, admis-
sions with an endocarditis code, followed by the longest
admission during the clinician-recorded endocarditis dates,
were chosen. 9/1541 (0.006%) patients reviewed in Leeds
could not be matched to any inpatient admission and were
not considered further (Additional file 1: Figure S1). JS and
RG had full access to the Leeds Endocarditis Service Data-
base and admissions with endocarditis codes in Leeds. NF
had access to an anonymised extract of the Leeds Endocar-
ditis Service Database and linked admissions with endocar-
ditis codes. NF had full access to the anonymised database
of admissions to Oxford with an endocarditis code and
linked blood culture results. NF also had full access to the
audit database of admissions to Oxford with an endocardi-
tis code and the audit prescription database. However, no
author had access to the underlying population of all ad-
missions to the two hospitals.
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Classifying readmissions
In the analysis of coding data vs confirmed clinical cases,
admissions that did not directly match a case of endo-
carditis were classified as readmissions for infective
endocarditis if the admission occurred within 30 days of
a discharge date from a spell with an endocarditis code.
If the patient had a previous diagnosis (determined by
the clinician) or previous admission with an endocarditis
code > 30 days previously, this was counted as a past his-
tory. Length of stay was calculated as calendar date of
discharge minus date of admission.
Improving case identification using administrative data
To improve identification of confirmed clinical cases
from electronic health records, based on the findings of
the comparisons of endocarditis-coded vs confirmed
clinical cases, we examined the utility of excluding short
stays, apparent readmissions and elective admissions.
Based on clinical experience, it was judged unlikely that
a patient with infective endocarditis would be admitted
and discharged alive in less than 5 days. In the Oxford
2010–2016 audit, there were no admissions < 3 days sur-
viving to discharge that represented a case. In Leeds, 373
endocarditis-coded admissions < 3 days survived to dis-
charge; only 3 (1%) were confirmed clinical cases. We
therefore considered a threshold of < 3 days (discharge
date minus admission date) to exclude implausible endo-
carditis-coded admissions.
A normal treatment plan for endocarditis would be at
least 6 weeks’ antibiotics. In the Oxford 2010–2016
audit, two admissions of < 6 weeks were confirmed clin-
ical cases—both patients needed emergency valve sur-
gery for the initial case of endocarditis, then developed
endocarditis of the new valve with different organisms
within 6 weeks, but after 30 days. As our aim was to in-
vestigate thresholds that minimised loss of true cases
(and prioritised preserving sensitivity), we considered a
threshold of < 30 days from the previous discharge date
to exclude readmissions.
Elective admissions were defined as admission method
11 (waiting list), 12 (booked) or 13 (planned) [34]. In
Oxford, 33 elective admissions with an endocarditis code
were identified; all were true elective admissions and 10
represented confirmed clinical cases, being elective
admissions for valvular surgery and postoperative endo-
carditis (5, 3 and 2 were admission methods 11, 12 and
13 respectively).
Identifying confirmed clinical cases from prescribing data in
Oxford
We searched for endocarditis cases using the mandatory
‘indication’ field which all clinicians have to complete to
prescribe an antibiotic on the electronic prescribing sys-
tem. We manually inspected the records of all patients
with a prescription January–December 2016 with indica-
tion matching text string ‘ndoca’, ‘ie’, ‘valve’, ‘aortic root’
and ‘vegetation’ (fuzzy text search) (Additional file 1:
Figure S3).
Statistical methods
Analyses were performed using STATA 13.1. Incidence
trends were estimated from annual counts using Poisson
regression as there was no evidence of overdispersion
(p > 0.4), using population data for Oxfordshire and the
Leeds area from the Office of National Statistics [36] for
each year from 2001 to 2016 as an offset (imputing 2001
data for 1999 and 2000 in Oxford).
Results
Less than half of admissions with an endocarditis code
recorded in electronic health records represented a
confirmed clinical case of infective endocarditis, driven
mostly by the I38 (endocarditis: valve unspecified) code
1681 and 1725 admissions with an endocarditis diagnostic
code in the primary or secondary position were identified
in Leeds (2006–2016) and Oxford (1999–2016), respect-
ively (Fig. 1, Additional file 1: Figure S1 and Figure S2). In
Leeds, 738/1681 (44%) endocarditis-coded admissions be-
tween 2006 and 2016 represented Duke definite/possible
cases (Fig. 2 and Table 2). In Oxford, 307/552 (56%)
reviewed admissions between 2010 and 2016 represented
Duke definite/possible cases (Figs. 1 and 2).
Some codes used in most endocarditis studies had good
predictive ability, but the frequently used I38 code
represented a confirmed clinical case in < 6% of
admissions
Not all diagnostic codes were equal—the code I33.0
(‘Acute and subacute infective endocarditis’) in the
primary position (‘the main condition treated or in-
vestigated during the relevant episode of healthcare’
[1]), included in most endocarditis studies (Add-
itional file 1: Table S2), represented a new case in
433/530 (positive predictive value (PPV) 82%) and
231/273 (PPV 85%) reviewed admissions in Leeds and
Oxford, respectively (Fig. 2). Non-I33.0 codes and
those in secondary positions performed less well, but
some rarer codes nevertheless represented true cases,
particularly in the primary position. Among endocar-
ditis secondary codes (‘all conditions that co-exist at
the time of admission, that develop subsequently, or
that affect the treatment received and/or the length
of stay’ [1]), the code I38 (‘Endocarditis, valve un-
specified’) was the most commonly used, but repre-
sented a new case in only 41/685 (PPV 6%) and 2/97
(PPV 2%) reviewed admissions in Leeds and Oxford,
respectively (Fig. 2); 619 (90%) and 80 (82%) respect-
ively had no mention of endocarditis in their medical
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notes, though many had some form of valvular heart
disease. Both centres showed an apparent increase in
the number of endocarditis-coded admissions over
time, with sudden spikes at different time points
(2015 in Leeds, 2012 in Oxford), driven largely by ad-
missions with a secondary I38 code (Fig. 1).
Discrepancies between codes and confirmed clinical cases
were mainly due to correctly assigned codes for
readmissions, past histories and investigations for
endocarditis (later excluded)
The majority of admissions with an endocarditis code
that were not confirmed clinical cases had legitimate
reasons for the code being assigned. A readmission or
relevant past history accounted for 190/1681 (11%)
and 53/552 (10%) endocarditis-coded reviewed admis-
sions in Leeds and Oxford, respectively (Fig. 2). Ad-
missions where infective endocarditis was investigated
and ruled out accounted for 101/1681 (6%) and 48/
552 (9%) admissions in Leeds and Oxford, respect-
ively. Discussions with the Oxford clinical coding
team confirmed the NHS Clinical Classifications Ser-
vice guidance [37] that a patient referred by a Gen-
eral Practitioner for ‘suspected endocarditis’, who had
the diagnosis later excluded with no other definitive
diagnosis confirmed would be correctly assigned a
primary I33.0 code.
I38: ‘Endocarditis: valve unspecified’ could be correctly
assigned even if endocarditis was never mentioned in the
notes due to indexing guidance
Review of the coding process identified that the
WHO ICD-10 Alphabetical index directs many non-
specific conditions towards an endocarditis code. For
instance, ‘Stenosis-> valve (cardiac)(heart) (see also
Endocarditis) I38’. This was discussed with the Clin-
ical Classifications Service, UK, the definitive source
of clinical coding guidance who set the national stan-
dards for ICD-10 used by the NHS, who responded:
‘a coder would be correct to assign code I38 when
indexing a documented diagnosis which leads the
coder to assign code I38, even when the term
Fig. 1 Numbers of admissions with endocarditis codes in Leeds and Oxford, compared to those of admissions that represent a new clinical case
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endocarditis is not documented within the medical
record’. (Full quote in Additional file 1: Extended
Methods.)
Secondary codes often represent Duke definite/possible
cases; primary codes miss a quarter of these cases
Patients who presented with embolic phenomena (e.g.
stroke or cerebral abscess) due to infective endocardi-
tis, or who developed infective endocarditis during an
admission for valve surgery or chemotherapy, were
commonly assigned a secondary endocarditis code,
and a primary code reflecting the presentation,
following coding guidelines. In Leeds and Oxford,
176/738 (24%) and 54/307 (25%) definite/possible cases
with an endocarditis diagnostic code had this as a se-
condary code, respectively (Additional file 1: Figure S1
and Figure S2).
A quarter of Duke definite/possible endocarditis cases
may not receive any endocarditis diagnostic code and are
not readily identifiable using electronic health records
In Leeds, there were 1001 Duke definite/possible
cases during 2006–2016 (Additional file 1: Table S4),
of which 263 (24%) did not have an endocarditis
diagnostic code associated with their admission (sensi-
tivity 76%). This occurred less commonly for Duke
definite (153/713 (21%)) versus Duke possible (110/288
(38%)) cases (p < 0.0001). Fifty-two (20%) missed cases
had the code ‘T82.7: Infection and inflammatory reaction
due to other cardiac and vascular devices, implants and
grafts’ present (primary/secondary), but other primary
codes covered a diverse range of infection, sepsis and
heart disease codes with no clear pattern (Additional file 1:
Figure S1).
In Oxford, an audit of 2016 electronic prescribing
records identified 10 additional cases above the 66 iden-
tified by diagnostic codes (Additional file 1: Figure S3)
(sensitivity 87%). Five had pacemaker lead infections
with a code indicating an infected device, two were can-
cer patients developing infective endocarditis as inpa-
tients, one had coding reflecting a septic, ischaemic foot
and intensive care management with endocarditis found
during the admission, one aortic root abscess had ‘arter-
itis’ written on a discharge summary and was coded as
such and one had coding for a mitral valve disorder with
streptococcal sepsis.
Fig. 2 Clinical status of patients with endocarditis-coded admissions in Leeds and Oxford
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Raw endocarditis-coded admission data can give inflated
estimations of incidence which can be mitigated by
curation using carefully selected codes and other
administrative data
Estimating cases of infective endocarditis using all admis-
sions and all endocarditis codes (as defined in Table 1)
overestimated the apparent incidence in Leeds during
2006–2016 by over twofold compared to confirmed clinical
cases in the Leeds service database (sensitivity/specificity/
positive predictive value [PPV] 0.74/0.47/0.44 respectively)
(Fig. 3 and Table 2).
We were able to substantially improve agreement be-
tween diagnostic codes and confirmed clinical cases by
removing codes with low predictive potential (particu-
larly I38 in a secondary position), very short admissions
(< 3 days) without death, and then (after excluding short
admissions) readmissions within 30 days of a previous
(endocarditis-coded) discharge date (for details, see Add-
itional file 1: Extended Methods). This combination sub-
stantially improved specificity and PPV, with only a
small loss in sensitivity for Duke definite/possible cases
in Leeds (0.69/0.89/0.78 respectively) (Table 2). Results
were broadly similar (PPV 0.77) in Oxford (Add-
itional file 1: Table S5).
The majority of studies of endocarditis incidence
use only the ICD-10 code I33.0, or I33.0 and I33.9
codes (or ICD-9 equivalents). Using I33.0 in any pos-
ition had similar specificity and PPV in the Leeds
data to the strategy above but with reduced sensitivity
(sensitivity/specificity/PPV 0.55/0.91/0.77) (Table 2).
The strategy with the highest PPV (88%) used I33.0
in the primary position alone [14, 38], but also re-
moved short stays, readmissions and elective admis-
sions. However, despite its high specificity (0.97), this
Table 2 Leeds data: Agreement between admissions and cases with coding combinations with short admissions, readmission and
elective admissions removed
Codes used Removal of admissions with:
< 3 day LOS Readmissions
< 30 days
Elective
status
True
positive
False
positive
True
negative
False
negative
Sensitivity Specificity PPV NPV
I33.0 primary only 433 97 1664 568 0.43 0.95 0.82 0.75
I33.0 primary only ✓ 431 67 1694 570 0.43 0.96 0.87 0.75
I33.0 primary only ✓ ✓ 426 65 1696 575 0.43 0.96 0.87 0.75
I33.0 primary only ✓ ✓ ✓ 406 57 1704 595 0.41 0.97 0.88 0.74
All primary codes 562 178 1583 439 0.56 0.90 0.76 0.78
All primary codes ✓ 559 114 1647 442 0.56 0.94 0.83 0.79
All primary codes ✓ ✓ 552 111 1650 449 0.55 0.94 0.83 0.79
All primary codes ✓ ✓ ✓ 529 96 1665 472 0.53 0.95 0.85 0.78
I33.0 in any position 549 162 1599 452 0.55 0.91 0.77 0.78
I33.0 in any position ✓ 547 125 1636 454 0.55 0.93 0.81 0.78
I33.0 in any position ✓ ✓ 540 117 1644 461 0.54 0.93 0.82 0.78
I33.0 in any position ✓ ✓ ✓ 514 102 1659 487 0.51 0.94 0.83 0.77
All primary and I33.0 secondary 669 242 1519 332 0.67 0.86 0.73 0.82
All primary and I33.0 secondary ✓ 666 172 1589 335 0.67 0.90 0.80 0.83
All primary and I33.0 secondary ✓ ✓ 658 163 1598 343 0.66 0.91 0.80 0.82
All primary and I33.0 secondary ✓ ✓ ✓ 629 141 1620 372 0.63 0.92 0.82 0.81
All codes except I38 secondary 697 299 1462 304 0.70 0.83 0.70 0.83
All codes except I38 secondary ✓ 694 209 1552 307 0.69 0.88 0.77 0.84
All codes except I38 secondary ✓ ✓ 686 196 1565 315 0.69 0.89 0.78 0.83
All codes except I38 secondary ✓ ✓ ✓ 653 168 1593 348 0.65 0.91 0.80 0.82
All codes 738 943 818 263 0.74 0.47 0.44 0.76
All codes ✓ 735 573 1188 266 0.73 0.68 0.56 0.82
All codes ✓ ✓ 726 538 1223 275 0.73 0.69 0.57 0.82
All codes ✓ ✓ ✓ 693 487 1274 308 0.69 0.72 0.59 0.81
Note: Total number of clinically confirmed endocarditis cases = true positives + false negatives (1001); total number of endocarditis admissions = sum of all four
columns (2762)
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strategy had reduced sensitivity (0.41) (Table 2 and
Additional file 1: Figure S4), and hence underesti-
mated overall incidence (Fig. 3). Including short stays,
readmissions and all elective admissions with the
I33.0 primary code, more similarly to studies on Eng-
lish HES data [14, 38], reduced the PPV to 82%.
Incidence trends depend on specific diagnostic coding
algorithms
There was strong evidence of upward trends in inci-
dence of uncorrected endocarditis-coded admissions per
100,000 population in Leeds (annual rate ratio, aRR =
1.07 (95% CI 1.03–1.12) p < 0.001), whilst confirmed
clinical cases occurred at much lower incidence and
showed smaller incidence increases (aRR = 1.03 (95% CI
0.97–1.09) p = 0.31). Estimating incidence using the
steps outlined above (removing codes with low predict-
ive power, short stays and readmissions) substantially
improved agreement between estimated and true inci-
dence of endocarditis, although it similarly tended to
overestimate incidence increases and suggest stronger
statistical evidence to support them (Fig. 3), whether
based on all codes except I38 secondary or using only
the highly specific I33.0 code in the primary position (al-
though the latter also tended to underestimate inci-
dence). Similar estimated incidence patterns were seen
in Oxford (Additional file 1: Figure S5), but as informa-
tion on confirmed clinical cases was only available from
2010 to 2016 in this dataset, no comparison in trends
was possible.
Estimating incidence of streptococcal endocarditis using
secondary codes can overestimate increases over time
Not unexpectedly, in endocarditis-coded admissions and
confirmed clinical cases, the most common organisms
associated with endocarditis were Streptococcus spp. and
Staphylococcus spp. There are no diagnostic codes for
the oral viridans group Streptococcus species, which are
most likely to be affected by changes in dental prophy-
laxis, so we were unable to compare trends in these or-
ganisms. Estimating the incidence of streptococcal
endocarditis based on the presence of secondary Strepto-
coccus codes in endocarditis-coded admissions suggested
an increase over time in both Leeds and Oxford
(p = 0.04 and p = 0.03 respectively, Fig. 4). This apparent
upward trend was not seen when the incidence of
streptococcal endocarditis was calculated using con-
firmed clinical cases in Leeds (p = 0.22) or using in-
formation from linked blood culture results in Oxford
(p = 0.41) (Figs. 4 and 5, Additional file 1: Figure S6 and
Figure S7).
Fig. 3 Incidence of endocarditis in Leeds as estimated by electronic health records, compared to the clinical case
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Increased use of secondary codes over time may
contribute to the apparent overestimation of
streptococcal cases
In Leeds, there was moderate agreement between
streptococcal codes and Streptococcus spp. as cause of
disease. Of 314 cases judged to be of single organism
streptococcal aetiology by the clinician, 201 (64%) had
an associated streptococcal code (kappa = 0.56), 94
(30%) had no organism code and 19 (6%) had a differ-
ent organism code (Additional file 1: Table S6; 91%
(201/220) agreement where a code was given). In
Oxford, overall agreement between linked blood culture
results and coded organisms was similar: of 183 endo-
carditis-coded admissions with a linked positive
streptococcal blood culture alone, 107 (58%) had a
Streptococcus code, 68 (37%) had no code and 8 (4%)
had another organism code (kappa = 0.43) (Add-
itional file 1 Table S7; 93% (107/115) agreement where
a code was given). Use of secondary/supplementary or-
ganism codes, and secondary codes overall, increased
substantially during the study period in both centres
(Additional file 1: Figure S8).
Discussion
Here, we aimed to use endocarditis as a clinically relevant
case study to explore the relationship between clinical cases
and diagnostic codes and quantify and understand discrep-
ancies. Investigation of the quality of coded infective endo-
carditis data in two large teaching hospitals, recorded
between 1999 and 2016, found that different diagnostic
codes vary widely in their accuracy at identifying confirmed
clinical cases. Poor specificity of coding data could be
explained by several legitimate coding practices; for
example, the coding protocol legitimately allows diag-
nostic codes with the word ‘endocarditis’ to be applied
to readmissions and investigations for infective endo-
carditis, and even to admissions with no endocarditis
issues at all. We have, however, shown that the overall
accuracy of coding data can be improved by careful and
critical selection of codes, removal of records with
Fig. 4 Comparison of endocarditis-coded admissions with a Streptococcus code, and confirmed clinical cases or blood culture data in Oxford
and Leeds
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implausibly short stays and removal of readmissions.
The study has also shown that using secondary/supple-
mentary codes to estimate incidence of streptococcal
endocarditis can give misleading incidence trends, likely
due to increasing use of such codes over time. When
used, the organism codes were reasonably accurate at
species level in the two centres included in this study;
this suggests they could be used to assess changes in
proportions of differently coded organisms over time,
provided there was careful consideration of potential
for large-scale changes in coding behaviour, such as incen-
tivisation to record specific organisms, in other studies.
Study strengths
This study, which used clinician-collected prospective data
in Leeds and retrospective audit data in Oxford, based on
objective clinical criteria, is the largest and most detailed
study of endocarditis coding accuracy to date with 2233
patient admissions reviewed, and is the first in a UK set-
ting. It is the first to identify and quantify the reasons for
discrepancies between admissions with a diagnostic code
and clinical cases. Another major study strength was the
availability of detailed microbiological data on causative
organism, via clinician-recorded cases in Leeds, and linked
microbiological data in Oxford.
Study limitations
Study limitations include the dual-centre nature of the
study, and the limited information on confirmed clinical
cases in Oxford. In Oxford, where secondary/supplemen-
tary codes were matched to blood culture data, mismatches
might also be due to patients having positive blood cultures
from infections other than endocarditis. The organism
codes do not identify the oral viridans group streptococci,
which are most relevant to changes in antibiotic policy, and
we did not attempt to identify them from coding data, fo-
cussing on genus-level comparisons. This study did not set
out to investigate temporal associations between changes in
antibiotic prophylaxis policy and endocarditis incidence,
due to limited power with only two centres, but to assess
the relationship between endocarditis-coded admissions
and confirmed clinical cases. Previous studies investigating
temporal associations using administrative coding data have
varied in their findings [12–14, 24, 27]. These studies
Fig. 5 Comparison of coded organism and clinician-recorded organism (Leeds) or blood culture organism (Oxford)
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benefit from far larger numbers than our study, although
generally they have not investigated the relationship be-
tween diagnostic codes and confirmed clinical case, except
for Toyoda et al. [19]. Most have used a restricted set of
codes with reasonable performance in our study (Add-
itional file 1: Table S2).
Comparisons to other studies
Two other US [19] and Canadian [39] studies of 1673
and 119 hospitalisations, respectively, have assessed the
accuracy of endocarditis diagnostic codes. Sensitivity and
PPV of the ICD-9 codes equivalent to those used here
(Table 1) were higher than in in our study (0.94/0.94
[19], 0.90/0.78 [39], 0.70/0.70 Leeds). Both the US [14]
and Canadian [39] studies also identified the poor pre-
dictive value of ‘Endocarditis, valve unspecified’ (ICD-9
424.9, corresponding to code I38), though they did not
identify the underlying cause. Previous meta-analyses of
coded data to identify healthcare-associated infections
have noted moderate sensitivity in detecting Clostridium
difficile infection (pooled sensitivity 76%, specificity 99%)
and surgical site infections (sensitivity 81% specificity
97%) [40]. A US study of sepsis coding compared to sep-
sis objective clinical criteria found that admissions with
sepsis codes had increased, which was not reflected in
incidence of admissions meeting sepsis clinical criteria,
possibly due to changes in coding behaviour [41].
There is one other large-scale infective endocarditis
study that used direct microbiological data rather than
administrative diagnostic codes via three population-
based surveys undertaken at different time periods [42];
it also found no increase in the proportion of cases
caused by streptococci. A much smaller study of 106 ad-
missions with infective endocarditis linked with corre-
sponding blood cultures suggested the proportions of
causative organisms were similar in coded and microbio-
logical data [43], similar to our results.
Supplementary codes in particular may be more sus-
ceptible to changes in coding behaviour, such as incenti-
visation to record more secondary codes [44, 45] (so-called
‘coding depth’) or specific organisms, or availability and
expertise of coding staff. However, analysis of incidence of
endocarditis attributed to specific organisms differs from
analysis of proportions of endocarditis with an organism
code that are attributed to specific organisms. The previous
study using English HES data [14] found that the propor-
tion of endocarditis cases with any supplementary causal
organism coded increased over time, particularly before
2009. Given our observations that trends in streptococcal
endocarditis based on use of supplementary coding may
not match that based on clinician-recorded cases, our study
supports the view that using these codes is unlikely to give
meaningful information on the incidence of organism-spe-
cific endocarditis. However, where changes are driven by
coding depth (i.e. more codes are recorded over time, but
with no specific preference for particular secondary/supple-
mentary codes over others), proportions should be rela-
tively unaffected.
Implications for electronic health record study design in
endocarditis
Our work suggests that studies investigating endocarditis
using electronic health record data should not use the
‘I38: Endocarditis: valve unspecified’ code in the secondary
position, further supporting the findings of Toyoda et al.,
since coding protocols allow it to be assigned to admis-
sions featuring non-specific valve disorders entirely unre-
lated to endocarditis. Of note, most previous studies of
endocarditis incidence did not use this code and are not
affected by the issue, although at least two studies have
used it [13, 46] (Additional file 1: Table S2).
Table 2 shows clearly the trade-offs between sensitiv-
ity, specificity and PPV in any coding algorithm. How
these are balanced may depend on the aims of any
particular study. If the goal is to maximise sensitivity to
assess overall incidence levels, then inclusion of second-
ary codes, and potentially manual review of secondary
codes with low positive predictive value, may be re-
quired, or risk missing 25–50% of cases. Where manual
review is impractical, then identifying the highest sensi-
tivity that maintains reasonable specificity and/or PPV
may provide the best balance. It is important to note
that whilst maximising PPV alone may appear attractive,
a very strict rule can achieve high PPV whilst missing
most true cases (low sensitivity), underestimating inci-
dence and with an uncertain impact on trends. Overall,
we consider that using all codes except I38 secondary
provides a good balance between PPV and sensitivity
(Fig. 3) in our data set.
Clinical and policy implications
Regarding the clinical concern that infective endocarditis
increased in England [14] and the USA [24] after
changes in antibiotic dental prophylaxis around 2007,
our work suggests that the major studies examining
endocarditis incidence have not used any poorly predictive
codes, but that the algorithms used could nevertheless
have overestimated incidence trends by including short
admissions/readmissions. In particular, moves to reduce
length of stay in English hospitals have been accompanied
by parallel increases in readmissions over the last decade
[47] with uncertain impact.
Given the discrepant findings of electronic health rec-
ord studies, work to definitively quantify the efficacy of
dental prophylaxis in preventing endocarditis may re-
quire a national registry of disease to be established, as
previously suggested, though these are not without their
drawbacks and concerns about data quality, and require
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significant resources. Alternatively, despite the signifi-
cant resources required, it may be that efforts to set up a
large-scale individually randomised controlled trial will
ultimately be required to test the benefits of antibiotic
prophylaxis.
Implications for electronic health record study design in
general
Our study illustrates clearly that using diagnostic codes
which appear to represent a disease entity based on
their code title without any attempt to validate these
codes to clinically confirmed cases can lead to very
large errors if done incautiously. This has relevance be-
yond the field of endocarditis and is applicable to any
study conducted using diagnostic codes to assess pat-
terns of disease. Without deduplication and careful
code choice, more than half the codes assigned can rep-
resent not cases, but readmissions, investigations where
the presumptive diagnosis is later ruled out and past
histories. A diagnostic code most definitely does not
necessarily equal a clinical case. Importantly, this does
not generally suggest problems with clinical coding per
se, only that the current clinical coding process has dif-
ferent goals to epidemiology, being primarily for reim-
bursement and recording of hospital activity, rather
than clinical diagnoses.
Secondary codes can be susceptible to changes in coding
behaviour, depending on the disease entity, including
measures to increase quality as well as ‘up-coding’ (choos-
ing the code worth the most) or ‘coding inflation’ (where
multiple secondary codes are used to increase reimburse-
ment), which have been reported in the UK and other
healthcare settings using these systems [44, 45, 48]. How-
ever, studies that aim to maximise inclusion of possible
cases should not automatically disregard them, as a sub-
stantial proportion of confirmed clinical cases may only
receive a secondary code, as in our endocarditis examples.
Recommendations for conducting observational stud-
ies using routinely collected health data already exist
[49] and include detailing validation study methodology
or providing references for this. In studies which use a
very large selection of diagnostic codes, it may not be
possible to validate every code, but at minimum, diag-
nostic codes that occur most commonly should be
monitored over time by centre, and unexpected
changes discussed with both coding and clinically
trained staff. Additionally, studies using coding would
benefit from a statement by authors which justifies the
chosen coding strategy based on available data and
highlights the limitations of their approach. Any clinical
decisions made using diagnostic code-based analyses
should also formally consider whether robust validation
of coding has been performed and review justification
for the chosen strategy.
Finally, it suggests more work is needed to explore
novel methods of improving case identification using
electronic health records, such as improving data linking
between admissions and microbiology results [30], using
natural language processing methods [50], machine
learning approaches [51]or healthcare process modelling
[52], and supporting efforts to share, evaluate and refine
these methods [53].
Conclusion
Our study comprehensively evaluates the accuracy of
clinical coding of infective endocarditis in two UK centres.
It highlights that diagnostic codes were never intended for
observational epidemiology, and ‘mission creep’ in their
use requires validation against other sources of data rather
than the assumption that verbal descriptions are clinically
meaningful. Their findings cannot be seen as definitive or
replacing other research methodologies. They are useful
as a relatively resource-light method of assessing issues
that demand closer attention where possible, or studying
issues where other research methods are infeasible. The
study should serve as a learning point for anyone wishing
to use diagnostic codes to assess patterns of disease, and
emphasises the need for improvements in how we define
clinical diagnoses using routinely collected data.
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